医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Evaluate Founder and CEO Receives PharmaVOICE 100 Award

2014年08月04日 PM10:00
このエントリーをはてなブックマークに追加


 

LONDON & BOSTON & TOKYO

Life science market intelligence company, Evaluate, Ltd., announced today that Founder and CEO, Dr. Jonathan de Pass, has been selected by PharmaVOICE magazine as one of the top 100 most inspirational and influential people in the Life Sciences Industry.

The PharmaVOICE 100 represents leaders from across the global life sciences industry. A panel of PharmaVOICE editors chose the winners based on their ability to inspire, motivate and influence corporate leadership, research and development, technology, creativity and marketing and strategy.

Dr. de Pass founded Evaluate, Ltd. and the EvaluatePharma service from the ground up in 1996. Since then, Evaluate has come to be regarded as a trusted leader in life science market intelligence, known for its expertise, creativity and customer service by most of the world’s global pharmaceutical companies. A career highlight for Dr. de Pass was winning the Queens Award for Enterprise in 2009, one of the UK’s most prestigious business awards.

“For the 10 years I have worked with Jonathan, he has not only motivated me to always improve the way we manage and grow our services but has been an excellent person to work alongside, learn from and most importantly be inspired by,” said Debbie Paul, CEO, EvaluatePharma USA, Inc.

To read the 2014 PharmaVOICE 100 profiles, visit www.pharmavoice.com.

About Evaluate Ltd.

Evaluate is the trusted source for life science market intelligence and analysis with exclusive consensus forecasts to 2020. We support life science and healthcare companies, financial institutions, consultancies and service providers in their strategic decision-making. Our services include EvaluatePharmaEvaluateClinical Trials and EvaluateMedTech. Our global team of dedicated healthcare analysts employs rigorous methodologies to deliver strategic commercial analysis. We make our services valuable by combining superior quality content, user-friendly reporting tools and outstanding customer service to solve client problems. Our award-winning editorial team, EP Vantage, leverages our market intelligence and analysis to cut through the noise, giving you daily opinion and insights. The Evaluate services enable the life science community to make sound business decisions about value and opportunity. For more information please visit www.evaluategroup.com. On Twitter: @evaluatepharma, @evaluatemedtech, @epclinicaltrial, @epvantage.

CONTACT

Evaluate and EP Vantage (for general questions)
Christine Lindgren
+1
617-866-3906
christine.lindgren@evaluategroup.com
or
Chempetitive
Group (for U.S. media)
Rachel Lear
+1 781-775-3640
+1
858-457-2436
rlear@chempetitive.com
or
Instinctif
Partners (for non-U.S. media)
Melanie Toyne Sewell
Gemma Howe
+44
(0) 20 7457 2020
evaluate@instinctif.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表